Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes
Author:
Publisher
Cureus, Inc.
Subject
Aerospace Engineering
Reference28 articles.
1. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications;Zheng Y;Nat Rev Endocrinol,2018
2. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas;Saeedi P;Diabetes Res Clin Prac,2019
3. A narrative review of potential future antidiabetic drugs: should we expect more?;Chikara G;Indian J Clin Biochem,2018
4. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus;Misra M;J Pharm Pharmacol,2013
5. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians;Qaseem A;Ann Intern Med,2017
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials;Frontiers in Endocrinology;2023-08-28
2. Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India;Revista da Associação Médica Brasileira;2023
3. Seguridad y efectividad de la dapagliflozina con otro inhibidor del SGLT-2: ¿qué decisión tomar?;Medicina de Familia. SEMERGEN;2022-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3